Detalles de la búsqueda
1.
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Lancet
; 395(10227): 888-898, 2020 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085823
2.
Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
J Virol
; 94(13)2020 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32295913
3.
Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
Bioorg Med Chem Lett
; 47: 128168, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34091041
4.
Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence.
Proc Natl Acad Sci U S A
; 115(30): E7139-E7148, 2018 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29987026
5.
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
J Infect Dis
; 221(7): 1117-1126, 2020 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31781762
6.
Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells.
J Virol
; 93(24)2019 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578289
7.
Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.
Bioorg Med Chem Lett
; 30(17): 127367, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32738976
8.
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
Bioorg Med Chem Lett
; 30(13): 127197, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32331932
9.
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Clin Infect Dis
; 59(12): 1657-65, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25266289
10.
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Clin Gastroenterol Hepatol
; 12(6): 1029-37.e5, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24120953
11.
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
J Hepatol
; 59(1): 31-7, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23454058
12.
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
J Hepatol
; 59(1): 11-7, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23439259
13.
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Clin Gastroenterol Hepatol
; 11(1): 81-87.e4; quiz e5, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23064222
14.
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Hepatology
; 56(3): 884-93, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22473713
15.
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrob Agents Chemother
; 56(3): 1170-81, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22155837
16.
Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy.
J Clin Invest
; 132(8)2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35230978
17.
Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons.
Neuron
; 53(5): 639-47, 2007 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17329205
18.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20074791
19.
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform.
SLAS Discov
; 26(5): 642-654, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33427012
20.
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity.
J Med Chem
; 64(8): 4709-4729, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33797924